2023 SABCS Highlights

CE / CME

Highlights From the 2023 San Antonio Breast Cancer Symposium

Physician Assistants/Physician Associates: 1.25 AAPA Category 1 CME credits

Nurses: 1.25 Nursing contact hours

Physicians: maximum of 1.25 AMA PRA Category 1 Credits

Pharmacists: 1.25 contact hours (0.125 CEUs)

Released: February 23, 2024

Expiration: February 22, 2025

Sara A. Hurvitz
Sara A. Hurvitz, MD, FACP
Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Activity

Progress
1 2
Course Completed

References

  1. Cardoso F, O’Shaughnessy J, McArthur H, et al. Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2- breast cancer: KEYNOTE-756. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS01-02.
  2. Cardoso F, McArthur H, Schmid P, et al. KEYNOTE-756: phase 3 study of neoadjuvant pembrolizumab or placebo + chemotherapy followed by adjuvant pembrolizumab or placebo + endocrine therapy for early-stage high-risk ER+/HER2- breast cancer. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA21.
  3. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  4. Loi S, Curigliano G, Salgado R, et al. Biomarker results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: an exploratory analysis of CheckMate 7FL. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS01-01.
  5. Loi S, Curigliano G, Salgado R, et al. A randomized, double-blind trial of nivolumab vs placebo with neoadjuvant chemotherapy followed by adjuvant endocrine therapy in patients with high-risk, ER+ HER2- primary breast cancer. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA20.
  6. Nelson DJ, Clark B, Munyard K, et al. A review of the importance of immune responses in luminal B breast cancer. Oncoimmunology. 2017;6:e1282590.
  7. Hortobagyi G, Stroyakovsky D, Yardley D, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS03-03.
  8. Ribociclib [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023.
  9. Slamon DJ, Stroyakovskiy D, Yardley DA, et al. Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR-positive/HER2 early breast cancer. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract LBA500.
  10. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
  11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.1.2024. nccn.org. Accessed February 12, 2024.
  12. Abemaciclib [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2023.
  13. Harbeck N, Rastogi P, O’Shaughnessy, et al. Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA17.
  14. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;[Epub ahead of print].
  15. Turner N, Reis-Filho J, Goetz M, et al. Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS03-06.
  16. Loi S, Johnston S, Arteaga C, et al. Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract PS06-01.
  17. Prat A, Chaudhury A, Solovieff N, et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies. J Clin Oncol. 2021;39:1458-1467.
  18. Kim S, Armand J, Safonov A, et al. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Rep. 2023;42:113198.
  19. Loi S, Niman S, Zdenkowski N, et al. Randomized phase II study of neoadjuvant nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in triple negative breast cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N). Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract LBA01-03.
  20. Voorwerk L, Sanders J, Keusters MS, et al. Immune landscape of breast tumors with low and intermediate estrogen receptor expression. NPJ Breast Cancer. 2023;9:39.
  21. Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2023[Epub ahead of print].
  22. Ignatiadis M, Bailey A, McArthur H, et al. Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS01-03.
  23. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090-1100.
  24. Mamounas E, Bandos H, White J, et al. Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS02-07.
  25. van Mackelenbergh MT, Loibl S, Untch M, et al. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2023;41:2998-3008.
  26. Hurvitz S, Loi S, O’Shaughnessy J, et al. HER2CLIMB-02: randomized, double-blind, phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS01-10.
  27. Borges VF, Ferrario C, Aucoin N, et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 2018;4:1214-1220.
  28. Tucatinib [prescribing information]. Bothell, WA: Seagen Inc; 2023.
  29. Murthy R, Borges VF, Conlin A, et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:880-888.
  30. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.
  31. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105-117.
  32. Groves MD. Leptomeningeal disease. Neurosurg Clin N Am. 2011;22:67-78.
  33. Nayar G, Ejikeme T, Chongsathidkiet P, et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget. 2017;8:73312-73328.
  34. Vaz Batista M, Pérez-García J, Garrigós L, et al. Trastuzumab deruxtecan in patients with HER2[+] or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis: results from cohort 5 of the DEBBRAH study. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract PS11-05.
  35. Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28:1840-1847.
  36. Jhaveri K, André F, Hamilton E, et al. Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08). Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract RF02-03.
  37. Bardia A, Hurvitz S, Press MF, et al. GS2-03 TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS2-03.
  38. Weisser NE, Sanches M, Escobar-Cabrera E, et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023;14:1394.
  39. Escrivá-de-Romaní S, Cejalvo JM, Alba E, et al. Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC). Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract LBO1-04.
  40. Escrivá-de-Romaní S, Alba E, Rodríguez-Lescure Á, et al. Antitumor activity of zanidatamab with palbociclib and fulvestrant in HER2+ hormone-receptor positive (HR+) metastatic breast cancer. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract PD18-10.
  41. Zhu C, Ling W, Zhang J, et al. Safety and efficacy evaluation of pertuzumab in patients with solid tumors. Medicine (Baltimore). 2017;96:e6870.
  42. Bouwer NI, Jager A, Liesting C, et al. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice. Breast. 2020;52:33-44.
  43. Patel R, Cascetta K, Klein P, et al. A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE). Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract RF02-01.
  44. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519-530.
  45. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055.
  46. Bardia A, Schmid P, Tolaney SM, et al. Clinical outcomes by age subgroups in the phase 3 TROPiCS-02 study of sacituzumab govitecan vs treatment of physician’s choice in HR+/HER2- metastatic breast cancer. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract PO5-21-09.
  47. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2023.
  48. Sedrak MS, Freedman RA, Cohen HJ, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin. 2021;71:78-92.
  49. Bardia A, Jhaveri K, Im S-A, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer: primary results from the randomised phase 3 TROPION-Breast01 trial. Presented at: 2023 European Society for Medical Oncology Congress; October 20-24, 2023. Abstract LBA11.
  50. Bardia A, Jhaveri K, Im S, et al. Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: results from TROPION-Breast01. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS02-01.
  51. Gui X, Zhao J, Ding L, et al. Assessing real-world safety concerns of sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system. Front Oncol. 2023;13:1276976.
  52. Rugo HS, Robson M, Im S-A, et al. Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: randomized open-label phase 2 KEYLYNK-009 study. Presented at: 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023. Abstract GS01-05.